PETAL protocol: a phase Ib study of pembrolizumab after transarterial chemoembolization in hepatocellular carcinoma.
Petros FessasBernhard ScheinerAntonio D'AlessioClaudia A M FulgenziJames KorolewiczCaroline WardPaul TaitRobert ThomasAlessio CortelliniRohini SharmaDavid J PinatoPublished in: Future oncology (London, England) (2023)
Transarterial chemoembolization (TACE) is the treatment of choice for intermediate-stage hepatocellular carcinoma (HCC). Recent data suggest that TACE may boost the efficacy of anti-PD-1 immunotherapy. The authors present the trial protocol for PETAL, a phase Ib study, which will assess the safety and bioactivity of pembrolizumab, an anti-PD-1 antibody, following TACE in HCC. After a run-in phase evaluating six patients to establish preliminary safety, up to 26 additional participants will be enrolled. Pembrolizumab will be administered three-times weekly for 1 year or until progression, starting 30-45 days after TACE. The primary objective is to determine safety and the secondary objective is to preliminarily evaluate efficacy. Radiological responses will be evaluated every four cycles. Clinical Trial Registration : NCT03397654 (ClinicalTrials.gov).
Keyphrases
- clinical trial
- radiofrequency ablation
- randomized controlled trial
- end stage renal disease
- advanced non small cell lung cancer
- ejection fraction
- newly diagnosed
- chronic kidney disease
- study protocol
- peritoneal dialysis
- phase iii
- big data
- liver metastases
- prognostic factors
- machine learning
- patient reported outcomes
- artificial intelligence
- tyrosine kinase